Hannah Ryles to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Hannah Ryles has written about Xenograft Model Antitumor Assays.
Connection Strength
0.083
-
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. Clin Cancer Res. 2017 Jun 01; 23(11):2856-2868.
Score: 0.029
-
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016 Jan; 6(1):96-107.
Score: 0.027
-
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clin Cancer Res. 2016 Feb 15; 22(4):948-60.
Score: 0.027